Predictive factors for HBsAg-negative seroconversion in chronic hepatitis B after antiviral therapy
10.3760/cma.j.cn501113-20231213-00278
- VernacularTitle:抗病毒治疗后慢性乙型肝炎HBsAg阴转的预测因子
- Author:
Lili WU
1
;
Zhiliang GAO
Author Information
1. 中山大学附属第三医院感染科，广州 510630
- Keywords:
Chronic hepatitis B;
Hepatitis B surface antigen;
Clinical cure;
Predictor
- From:
Chinese Journal of Hepatology
2024;32(2):186-192
- CountryChina
- Language:Chinese
-
Abstract:
Hepatitis B surface antigen (HBsAg) negative seroconversion (HBsAg < 0.05 IU/ml) is research hotspot in the field of hepatitis at this stage, and patients who achieve HBsAg negative seroconversion have significantly fewer liver-related complications. Presently, there are many studies with regard to HBsAg-negative seroconversion, but there are still relatively few indicators used in clinical practice to predict HBsAg-negative seroconversion. Low baseline HBsAg quantification and dynamic decline during treatment are currently recognized as the best indicators for predicting HBsAg-negative seroconversion. However, other factors such as viral genotype, elevated transaminases during treatment course, immune cell function and cytokine levels, and host factors can all influence HBsAg-negative seroconversion. This article reviews the relevant indicators and potential predictive factors for HBsAg-negative seroconversion.
